Last reviewed 2026-04-23 · How we verify

CIK Cell

CIK cells are a type of adoptive cell therapy that stimulate the immune system to attack cancer cells.

CIK cells are a type of adoptive cell therapy that stimulate the immune system to attack cancer cells. Used for Treatment of various types of cancer, including leukemia, lymphoma, and solid tumors.

At a glance

Mechanism of action

CIK cells are a type of immune cell that can recognize and kill cancer cells. They work by activating the immune system to produce cytokines, which help to eliminate cancer cells. This approach is often used in the treatment of various types of cancer.

Approved indications

• Treatment of various types of cancer, including leukemia, lymphoma, and solid tumors

Common side effects

• Fever
• Fatigue
• Nausea

Key clinical trials

• CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction (NA)
• Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer. (EARLY_PHASE1)
• An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer (PHASE1)
• Immune Cell Therapy for Advanced Solid Tumors (PHASE1, PHASE2)
• A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced Bladder Cancer
• Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer (PHASE2)
• The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous CIK Cells (PHASE1, PHASE2)
• Optimizing Cytokine-Induced Killer Cells in Glioblastoma Patients

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.